Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SZ09904
- Development stage
- Preclinical
- Lead developer
- Sarfez Pharmaceuticals
- Modality
- Small Molecules
01
Overview
**SZ09904** is a preclinical, investigational fixed-dose combination developed by Sarfez Pharmaceuticals for neurogenic hypertension and hypertension associated with sympathetic nervous system activation. Sarfez identifies the asset as an FDC comprising multiple new chemical entities, but has not publicly disclosed the individual active ingredients, molecular targets, pharmacologic mechanisms, formulation, or route of administration. Public drug-pipeline listings likewise identify SZ-09904 as a Sarfez preclinical chemical-drug program for hypertension. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/dce8697edcb1417ba019f28652d29fe5))
- Other names
- SZ 09904SZ09904SZ-09904
Beyond the preview
Go deeper on SZ09904.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SZ09904.